WO1994017792A3 - Compositions and methods for transdermal drug delivery - Google Patents

Compositions and methods for transdermal drug delivery Download PDF

Info

Publication number
WO1994017792A3
WO1994017792A3 PCT/US1994/000896 US9400896W WO9417792A3 WO 1994017792 A3 WO1994017792 A3 WO 1994017792A3 US 9400896 W US9400896 W US 9400896W WO 9417792 A3 WO9417792 A3 WO 9417792A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
drug delivery
transdermal drug
iontophoresis
Prior art date
Application number
PCT/US1994/000896
Other languages
French (fr)
Other versions
WO1994017792A2 (en
Inventor
Harold E Selick
Kevin R Oldenburg
Original Assignee
Affymax Tech Nv
Harold E Selick
Kevin R Oldenburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affymax Tech Nv, Harold E Selick, Kevin R Oldenburg filed Critical Affymax Tech Nv
Priority to AU67647/94A priority Critical patent/AU6764794A/en
Priority to JP6518085A priority patent/JPH08510720A/en
Priority to EP94915749A priority patent/EP0683668A4/en
Publication of WO1994017792A2 publication Critical patent/WO1994017792A2/en
Publication of WO1994017792A3 publication Critical patent/WO1994017792A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Abstract

The present invention relates to methods of delivering nucleotide-based pharmaceutical agents across membranes, such as the dermis or skin layer of a patient using iontophoresis.
PCT/US1994/000896 1993-01-27 1994-01-26 Compositions and methods for transdermal drug delivery WO1994017792A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU67647/94A AU6764794A (en) 1993-01-27 1994-01-26 Compositions and methods for transdermal drug delivery
JP6518085A JPH08510720A (en) 1993-01-27 1994-01-26 Compositions and methods for transdermal drug delivery
EP94915749A EP0683668A4 (en) 1993-01-27 1994-01-26 Compositions and methods for transdermal drug delivery.

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US946393A 1993-01-27 1993-01-27
US08/009,463 1993-01-27
US7729693A 1993-06-14 1993-06-14
US7778693A 1993-06-14 1993-06-14
US08/077,786 1993-06-14
US08/077,296 1993-06-14
US10732993A 1993-08-16 1993-08-16
US08/107,329 1993-08-16

Publications (2)

Publication Number Publication Date
WO1994017792A2 WO1994017792A2 (en) 1994-08-18
WO1994017792A3 true WO1994017792A3 (en) 1994-09-29

Family

ID=27485882

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/000896 WO1994017792A2 (en) 1993-01-27 1994-01-26 Compositions and methods for transdermal drug delivery

Country Status (5)

Country Link
EP (1) EP0683668A4 (en)
JP (1) JPH08510720A (en)
AU (1) AU6764794A (en)
CA (1) CA2153243A1 (en)
WO (1) WO1994017792A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348449B1 (en) * 1993-09-21 2002-02-19 The Trustees Of The University Of Pennsylvania Methods of inducing mucosal immunity
US5942395A (en) * 1997-05-09 1999-08-24 Universite De Montreal Hybrid ribozymes and methods of use
DE19814257A1 (en) * 1998-03-31 1999-10-07 Asta Medica Ag effervescent formulations
KR20010106462A (en) * 1998-09-01 2001-11-29 체에베체 그레고르 Electrically controlled transport of charged penetrants across barriers
AU2007280690C1 (en) 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
US8530436B2 (en) 2007-01-29 2013-09-10 Transderm, Inc. Methods and compositions for transdermal delivery of nucleotides
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
AU2009210266B2 (en) 2008-01-31 2015-01-29 CureVac SE Nucleic acids comprising formula (NuGlXmGmGnNv)a and derivatives thereof as an immunostimulating agents/adjuvants
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
DK2449113T3 (en) 2010-07-30 2016-01-11 Curevac Ag Complex formation of nucleic acids with the disulfide cross-linked cationic components for transfection and immunostimulation
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
AU2014310934B2 (en) 2013-08-21 2019-09-12 CureVac SE Respiratory syncytial virus (RSV) vaccine
US10369216B2 (en) 2014-04-01 2019-08-06 Curevac Ag Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU609769B2 (en) * 1987-02-10 1991-05-09 Drug Delivery Systems Inc. Electrolytic transdermal delivery of proteins
US5085749A (en) * 1989-03-14 1992-02-04 Massachusetts Institute Of Technology Dynamically controlled membrane
WO1990012022A1 (en) * 1989-03-31 1990-10-18 University Patents, Inc. Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections
US5248670A (en) * 1990-02-26 1993-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides for inhibiting herpesviruses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5042975A (en) * 1986-07-25 1991-08-27 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Journal of Controlled Release, Volume 7, issued 1988, A.K. BANGA et al., "Iontophoretic Delivery of Drugs: Fundamentals, Developments and Biomedical Applications", pages 1-24, see the entire document. *
Nature, Volume 355, issued 06 February 1992, L.C. BOCK et al., "Selection of Single-Stranded DNA Molecules that Bind and Inhibit Human Thrombin", pages 564-566, see the entire document. *
Pharmaceutical Research, Volume 9, No. 10 (Supplement), issued October 1992, R. VAN DER GEEST et al., "Iontophoresis: A Transdermal Delivery Strategy for Antisense Oligonucleotide Drugs?", page S-67, Abstract BIOTEC 2004, see entire Abstract. *
Proceedings of the National Academy of Sciences, USA, Volume 84, issued November 1987, P.L. FELGNER et al., "Lipofection: A Highly Efficient, Lipid-Mediated DNA-Transfection Procedure", pages 7413-7417, see the entire document. *
See also references of EP0683668A4 *
The Journal of Infectious Diseases, Volume 154, No. 6, issued December 1986, L.P. GANGAROSA, Sr. et al., "Iontophoresis of Vidarabine Monophosphate for Herpes Orolabialis", pages 930-934, see the entire document. *

Also Published As

Publication number Publication date
WO1994017792A2 (en) 1994-08-18
EP0683668A4 (en) 1997-12-29
AU6764794A (en) 1994-08-29
JPH08510720A (en) 1996-11-12
EP0683668A1 (en) 1995-11-29
CA2153243A1 (en) 1994-08-18

Similar Documents

Publication Publication Date Title
MX9602656A (en) Transdermal device containing polyvinylpyrrolidone as solubility enhancer.
PL330212A1 (en) Preparation administered by transcutaneous absorption
AU4923500A (en) Device and method for increasing the transdermal permeation of medicaments
WO1994017792A3 (en) Compositions and methods for transdermal drug delivery
EP1234586A3 (en) Hepatoselective pharmaceutical actives
AU4261097A (en) Compositions and methods for topical application of therapeutic agents
AU2506388A (en) Azelastine-containing medicaments for application in the nose and/or at the eye
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
WO2000038626A3 (en) Substrate composition and method of use for sequestration of skin irritants
ATE288743T1 (en) PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR ADMINISTRATION OF ACTIVE INGREDIENTS TO MUCOUS SKIN SURFACES
HUP9904023A2 (en) Use of leptin antagonists for treating insulin resistance in type ii diabetes
EP0147146A3 (en) Enhancement of transdermal drug delivery
EP0160501A3 (en) Sustained release intranasal formulation and method of use thereof
AU7662400A (en) Transdermal therapeutic system containing tulobuterol hydrochloride for administering the bronchodilator tulobuterol via the skin
EP0387693A3 (en) Transdermal system with stepwise drug release, and its use in local or systemic cosmetic administration
ZA968905B (en) Transdermal therapeutic system (tts) for administering active substances for drug dependence or drug addiction
ATE208200T1 (en) TRANSDERMAL THERAPEUTIC SYSTEM (TTS) FOR ADMINISTRATION OF TESTOSTERONE
HUP9802897A3 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient
EP0744176A3 (en) Methods for inhibiting bone loss
EP0227531A3 (en) Pyroglutamic acid esters used as dermal penetration enhancers for drugs
WO2002058532A3 (en) Method for identifying ligands to lxr-receptor that stimulates pre-adipocyte differentiation and formulations thereof
WO1997017072A3 (en) Use of flupirtin for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system
ZA987006B (en) Transdermal therapeutic system (TTS) for delivering active ingredient through the skin to a body and method for application to the skin
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
DE69431430T2 (en) Factor XIII for the treatment of skin wounds

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US US US US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US US US US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2153243

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994915749

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1995 495490

Country of ref document: US

Date of ref document: 19950926

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1994915749

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994915749

Country of ref document: EP